- €1.44bn
- -€1.67bn
- €275.65m
- 36
- 19
- 72
- 33
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 0.5 | ||
| Price to Tang. Book | 0.54 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 5.22 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -4.96% | ||
| Return on Equity | -0.05% | ||
| Operating Margin | -68.33% | ||
Financial Summary
| Year End 31st Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | €m | 530.26 | 538.6 | 277.38 | 239.72 | 275.65 | 267.75 | 266.17 | -20.82% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | +106.75 | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Galapagos NV is a Belgium-based clinical-stage biotechnology company. The Company is engaged in the discovery and development of small molecule medicines with modes of action. Its pipeline comprises Phase 3, 2, 1, pre-clinical studies and discovery small-molecule and antibody programs in cystic fibrosis, inflammation, and other indications. The Company focuses on developing a portfolio of clinical-stage therapies for the enhancement of existing treatment paradigms. It develops transformational medicines in areas of high unmet need by combining internal with external science with the goal to add years of life and improve of life of patients across the globe. It discovers which proteins that are involved in causing diseases such as, rheumatoid, arthritis, inflammatory bowel disease and fibrosis. The Company acquired CellPoint and AboundBio in order to develop a cell therapy, which is a potential transformative treatment of different types of cancer.
Directors
- Onno van de Stolpe CMG (61)
- Rajesh Parekh NEC (61)
- Bart Filius PRE (50)
- Walid Abi-Saab EXB (55)
- Andre Hoekema EXB (63)
- Michele Manto EXB (48)
- Linda Higgins NED (58)
- Daniel O' Day NED (58)
- Katrine Bosley NID (52)
- Peter Guenter NID (58)
- Mary Kerr NID (60)
- Howard Rowe NID (51)
- Elisabeth Svanberg NID (61)
- Last Annual
- December 31st, 2024
- Last Interim
- December 31st, 2024
- Incorporated
- July 6th, 1999
- Public Since
- May 6th, 2005
- No. of Employees
- 704
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
Euronext - Amsterdam- Shares in Issue
- 65,897,071
- Address
- Generaal De Wittelaan L11 A3, MALINES (MECHELEN), 2800
- Web
- https://www.glpg.com/
- Phone
- +32 15342900
- Auditors
- BDO Bedrijfsrevisoren BV
Upcoming Events for GLPG
Q1 2025 Galapagos NV Earnings Call
Galapagos NV Annual Shareholders Meeting
Galapagos NV Annual Shareholders Meeting
Galapagos NV at RBC Capital Markets Global Healthcare Conference
Half Year 2025 Galapagos NV Earnings Release
Half Year 2025 Galapagos NV Earnings Call
Similar to GLPG
Themis Bioscience BV
Euronext - Amsterdam
Vivoryon Therapeutics NV
Euronext - Amsterdam
FAQ
What is the Galapagos NV share price?
As of Today at 20:44 UTC, shares in Galapagos NV are trading at €21.84. This share price information is delayed by 15 minutes.
How has the Galapagos NV share price performed this year?
Shares in Galapagos NV last closed at €21.84 and the price had moved by -20.23% over the past 365 days. In terms of relative price strength the Galapagos NV share price has underperformed the FTSE Global All Cap Index by -21.64% over the past year.
What are the analyst and broker recommendations for Galapagos NV?
The overall consensus recommendation for Galapagos NV is Hold. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the Galapagos NV dividend yield?
Galapagos NV does not currently pay a dividend.
Does Galapagos NV pay a dividend?
Galapagos NV does not currently pay a dividend.
When does Galapagos NV next pay dividends?
Galapagos NV does not currently pay a dividend.
How do I buy Galapagos NV shares?
To buy shares in Galapagos NV you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Galapagos NV?
As of the previous close price of €21.84, shares in Galapagos NV had a market capitalisation of €1.44bn.
Where are Galapagos NV shares listed?
Here are the trading details for Galapagos NV:
- Country of listing: Netherlands
- Exchange: AEX
- Ticker Symbol: GLPG
What kind of share is Galapagos NV?
Based on an overall assessment of its quality, value and momentum Galapagos NV is currently classified as a Momentum Trap. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Galapagos NV share price forecast for 2025?
The analyst consensus target price for shares in Galapagos NV is €30.30. That is 38.74% above the last closing price of €21.84.
Analysts covering Galapagos NV currently have a consensus Earnings Per Share (EPS) forecast of -€1.08 for the next financial year.
Find out moreWhat is the trend in the Galapagos NV share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Galapagos NV. Over the past six months, its share price has underperformed the FTSE Global All Cap Index by -19.7%.
As of the last closing price of €21.84, shares in Galapagos NV were trading -11.97% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Galapagos NV PE Ratio?
The Galapagos NV PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at €21.84.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Galapagos NV?
Galapagos NV's management team is headed by:
- Onno van de Stolpe - CMG
- Rajesh Parekh - NEC
- Bart Filius - PRE
- Walid Abi-Saab - EXB
- Andre Hoekema - EXB
- Michele Manto - EXB
- Linda Higgins - NED
- Daniel O' Day - NED
- Katrine Bosley - NID
- Peter Guenter - NID
- Mary Kerr - NID
- Howard Rowe - NID
- Elisabeth Svanberg - NID